Drotrecogin alfa (activated): real-life use and outcomes for the UK.

ABSTRACT:

Introduction

In March 2001, the results of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study were published, which indicated a 6.1% absolute reduction in 28-day mortality. Drotrecogin alfa (activated; DrotAA) was subsequently approved for use in patients with severe sepsis.

Methods

In December 2002, critical care units in England, Wales and Northern Ireland were invited to participate in an audit of DrotAA. Data for each infusion of DrotAA were linked to case mix and outcome data from a national audit. Use of DrotAA was described and a nonrandomized comparison of effectiveness was conducted.

Results

1,292 infusions of DrotAA were recorded in 112 units; 61% commenced during the first 24 hours in the unit. The majority (77%)

SUBMITTER: Rowan KM 

PROVIDER: S-EPMC2447613 | biostudies-literature | 2008

REPOSITORIES: biostudies-literature